Royalty Report: Drugs, Disease, Therapeutic – Collection: 234445


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Blood Clotting
  • cell therapy
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 234445

License Grant
Licensee today announced that it has expanded its existing clinical collaboration agreement with Japanese Licensor to develop AndexXaâ„¢ (andexanet alfa) as an antidote for edoxaban, Licensor's Factor Xa inhibitor.

The parties agreed to amend the agreement to expedite the expansion of our Phase 4 trial of Andexxa.  The original agreement was entered into to study the safety and efficacy of Andexxa as a reversal agent to edoxaban, in our Phase 3 and Phase 4 studies.  The Licensee is responsible for the cost of conducting these clinical studies. Pursuant to our agreement with Licensor, Licensee is obligated to provide research, development and regulatory services and to manufacture and supply Andexxa.

License Property
Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban.

AndexXa (andexanet alfa), an investigational drug, is a modified human Factor Xa molecule that acts as a decoy to target and sequester with high specificity both oral and injectable Factor Xa inhibitors in the blood. Once bound, the Factor Xa inhibitors are unable to bind to and inhibit native Factor Xa, thus potentially allowing for the restoration of normal hemostatic processes. AndexXa is the first compound being studied as an antidote for Factor Xa inhibitors that directly and specifically reverses anti-Factor Xa activity – the anticoagulant mechanism of these agents.

Field of Use
This agreement pertains to the drug industry relating to therapeutics in the areas of thrombosis, other hematologic disorders and inflammation.

Licensee is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, for patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as for life-threatening or uncontrolled bleeding or emergency surgery and urgent procedures.

IPSCIO Record ID: 79329

License Grant
Licensor granted exclusive rights to develop and commercialize andexanet alfa in Japan. Licensor and Licensee are responsible for all development, regulatory and commercial activities in Japan which may also include research and development activities specific to Factor Xa inhibitors other than apixaban.

Pursuant to this agreement, we are obligated to provide certain research and development activities outside of Japan, provide clinical drug supply and related manufacturing services and to participate on various committees.

License Property
Andexanet alfa is an FDA-designated breakthrough therapy and orphan drug, is a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor.

Andexanet alfa is a drug under investigation as a potential antidote for factor Xa inhibitors, a group of anticoagulant (anti–blood clotting) drugs that includes rivaroxaban, apixaban and edoxaban.

IPSCIO Record ID: 225746

License Grant
The Licensee entered into an agreement to license from the Licensor certain exclusive rights to research, develop and commercialize certain compounds that inhibit fXa, including betrixaban. Betrixaban is used in thrombosis pateints, as it significantly reduces the risk of venous thromboembolism and VTE-related events without an increase in major bleeding.
License Property
Bevyxxa® (betrixaban) is an oral, once-daily Factor Xa, or fXa, inhibitor (anticoagulant) for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism. in the field of thrombosis, as it significantly reduces the risk of VTE and VTE-related events without an increase in major bleeding.
Field of Use
The Licensee will develop and commercialize betrixaban.

IPSCIO Record ID: 201028

License Grant
The development and commercialization agreement is to develop and commercialize ELOCTATE and ALPROLIX globally.  Each party have specific territories.
License Property
ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], are extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor, thereby making the product last longer in a persons blood than traditional factor therapies.
Field of Use
The agreement is for the drug industry, specifically for clotting-factor therapies.

Elocta is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.